GyrB-IN-1 is a DNA gyrase (GyrB) inhibitor. GyrB-IN-1 shows an IC50 of 19.1 μM against Mycobacterium smegmatis GyrB ATPase activity and 21.9 μM against Mycobacterium tuberculosis GyrB DNA supercoiling activity. GyrB-IN-1 exerts antimycobacterial activity and has cytotoxicity. GyrB-IN-1 can be used for the research of tuberculosis.

GW583340 (compound 6) is an orally active ErbB-2/EGFR tyrosine kinase inhibitor. GW583340 exhibits antitumor activity in xenograft models with EGFR overexpression or ErbB-2 overexpression. GW583340 is applicable to research related to head and neck cancer, breast cancer, and gastric cancer.

GW-5823 is a selective CCK-AR agonist with an EC50 of 70 nM. GW-5823 can be studied in research on obesity.

Guraxetan-NH-PEG3-TFP ester (Fig.3) is a chelating agent and linker conjugate that can be used in the synthesis of radiopharmaceuticals.

Guanosine 5'-triphosphate 3'-diphosphate is a guanine nucleotide that participates in RNA synthesis and protein synthesis.

GSK 1997132B is a benzimidazole-based PPARγ partial agonist that can cross the blood-brain barrier with a pEC50 value of 8.0. GSK 1997132B has no significant effect on PPARα/δ. GSK 1997132B improves the problem of high blood clearance rate of earlier compounds, avoiding side effects such as weight gain and edema. GSK 1997132B can be used for research on Alzheimer's disease.

GRI918013 (compound 1) is a selective and competitive autotaxin (ATX/NPP2) inhibitor with anti-invasive and anti-metastatic activity. GRI918013 competitively binds to ATX, blocking lipid substrates such as lysophosphatidylcholine (LPC) from entering the ATX active site, thereby inhibiting ATX-mediated hydrolysis of LPC to lysophosphatidic acid (LPA), and consequently inhibiting ATX-LPA axis-related tumor cell invasion and metastasis. GRI918013 inhibits ATX-mediated hydrolysis of the LPL substrate FS-3 (IC50=31.42 nM, Ki=12.98 nM). GRI918013 can be used in research on cancer invasion and metastasis, such as melanoma, and can also serve as a tool compound for ATX-LPA axis-related diseases such as fibrotic diseases, neuropathic pain, and cholestatic pruritus.

Graviquinone is a Chk1 inhibitor. Graviquinone exhibits potent cytotoxicity against various cancer cell lines. Graviquinone possesses the characteristics of bypassing ABCB1-mediated multidrug resistance, selectively damaging cancer cell DNA, and regulating the DNA damage response. Graviquinone can also enhance cytotoxicity by increasing ROS levels in cancer cells. Graviquinone can be used for cancer research.

GPX4 degrader-1 (Compound RS-1) is a hydrophobic tagging (HyT)-mediated GPX4 degrader (DC50: 8.9 nM in HT1080 cells) GPX4 degrader-1 induces GPX4 degradation. GPX4 degrader-1 induces Ferroptosis. GPX4 degrader-1 increases lipid ROS. GPX4 degrader-1 demonstrates potent antitumor efficacy in a murine mammary carcinoma model.

GPR84 antagonist 10 (compound 1) is a potent and orally active GPR84 antagonist. GPR84 antagonist 10 can be used to study GPR84-dependent diseases, such as inflammation-driven pain diseases.

GPR6 inverse agonist 2 (Compound 575) is a selective GPR6 inverse agonist, with IC50 values of < 0.1 μM and 1~30 μM against GPR6 and GPR3, respectively. GPR6 inverse agonist 2 exhibits preliminary cardiac safety, with an IC50 of 21.71 μM for hERG. GPR6 inverse agonist 2 can be used in the research of movement disorders such as Parkinson's disease.

GP130 (G130) is a psychostimulant agent, exhibiting antagonist activity against central nervous system depressing agents[2.

Gly-PEG3-BA is an EML4-ALK PROTAC degrader. Gly-PEG3-BA effectively reduces EML4-ALK with a DC50 value of 0.50 μM in H3122 (EML4-ALK) cells. Gly-PEG3-BA effectively reduces EGFR mutant (L858R/T790M) levels with a DC50 of 20.15 μM in H1975 (EGER-L858R/T790M) cells. Gly-PEG3-BA exerts potent antiproliferation activity in H3122 (EML4-ALK) and H1975 (EGER-L858R/T790M) cells with IC50s value of 0.84 and 20.74 μM. Gly-PEG3-BA can be used for non-small lung cancer research.

Glutathioselenol (GS-SeH) is a nucleoside metabolite.

Glutathionylaminopropylcadaverine is a key biomarkers distinguishing stage II and stage III thyroid cancer.

Glucosaminylmuramyl dipeptide (GMDP) is a synthetic analogue of muramil-dipeptide. Glucosaminylmuramyl dipeptide inhibits 5'-nucleotidase activity. Glucosaminylmuramyl dipeptide produces marked antitumor effect. Glucosaminylmuramyl dipeptide can be used in sepsis research.

Glucagon receptor antagonist-8 (Compound 1) is a human glucagon receptor and p38 mitogen-activated protein (MAP) kinase antagonist, with IC50s of 0.27 μM and 0.16 μM, respectively.

GLP-1R-agonist-43 (Compound A) is an orally active GLP-1R agonist with an EC50 of 2.68 nM. GLP-1R-agonist-43 can be used in the research of non-insulin-dependent diabetes mellitus (type 2 diabetes) and obesity.

GLP-1R agonist 44 is a glucagon-like peptide-1 receptor (GLP-1R) agonist. GLP-1R agonist 44 can be used for the research of diseases related to GLP-1R, such as type 2 diabetes, obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, nephropathy, gout, hematuria, cardiovascular disease.

GLP-1R agonist 35 (Compound 111-2) is a GLP-1R agonist with an EC50 of 0-10 nM. GLP-1R agonist 36 can be used for the studies of diabetes and obesity.

GLP-1 receptor agonist 18 is an orally active GLP-1 receptor agonist with an EC50 of 0.22 nM. GLP-1 receptor agonist 18 can reduces blood sugar levels and body weight. GLP-1 receptor agonist 18 can be used for the research of diabetes.

Ginsenoside C-K hexapropionate ester (Structure 2) is a selective agonist of LXRα, with no significant activation effect on LXRβ. Ginsenoside C-K hexapropionate ester upregulates the expression of downstream genes such as ABCA1 by activating LXRα, promoting reverse cholesterol transport, and reducing lipid deposition in macrophage-derived foam cells. It can be used in the research of atherosclerosis. Ginsenoside C-K hexapropionate ester is a derivative synthesized from ginsenoside Compound K, an active metabolite of Panax notoginseng saponins, by modification with propionic anhydride.

Ganglioside GD1b (porcine brain) (diammonium) is a glycosphingolipid.

G6PD-IN-2 is a Plasmodium falciparum glucose-6-phosphate dehydrogenase (G6PD) inhibitor with an IC50 value of 0.2 μM. G6PD-IN-2 exerts weak inhibitory activity on Plasmodium falciparum glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase (PfGluPho) with an IC50 value of 22.0 μM. G6PD-IN-2 inhibits growth of Plasmodium falciparum 3D7 strain and exhibits low cytotoxicity in hepatocytes. G6PD-IN-2 can be used for the research of malaria.

FXR agonist 15 is a selective, potent and orally active farnesoid X receptor (FXR) agonist with EC50 of 0.76 μM. FXR agonist 15 exhibits no obvious activation on other nuclear receptors including LXRα/β, PXR, PPARα/β/γ, THR-β, with EC50 values all >10 μM. FXR agonist 15 can alleviate steatosis, lobular inflammation, hepatocyte ballooning and liver fibrosis. FXR agonist 15 can be used for the research of nonalcoholic steatohepatitis (NASH).

FPL 66564 is a short-acting angiotensin-converting enzyme (ACE) inhibitor with an IC50 of 5.7 nM against rabbit ACE. FPL 66564 inhibits ACE activity at the functional level and is hydrolyzed in human blood into inactive hydrophilic metabolites. FPL 66564 modulates angiotensin I-induced pressor responses in anesthetized rats, and its effects rapidly return to baseline after cessation of intravenous infusion. FPL 66564 can be used for research on cardiovascular regulation related to critical illness.

Formylphosphonic acid is a nucleoside metabolite.

Fonsartan (HR720) is an AT1 receptor antagonist. Fonsartan can be used for the study of myocardial infarction (MI).

Fmoc-NH-C2-diphosphate-dexamethasone (Compound 17) is a derivative of Dexamethasone and can be used as a drug intermediate for the synthesis of the Raltitrexed-Dexamethasone conjugate.

Fmoc-Gly-Gly-Phe-Gly-Docetaxel (compound 16h-3) is a drug-linker conjugate for ADC, which comprises a microtubule depolymerization inhibitor and a linker. Puxitatug samrotecan drug-linker can be used to synthesize antibody-drug conjugate (ADC).